DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Read / Leggi Disclaimer

BBAI BigBear.ai Holdings Inc

bbai

BigBear.ai started as a data-fusion and analytics contractor, grew via acquisitions and went public through the GigCapital4 SPAC at the end of 2021. The company’s value proposition is to make sense of messy data streams and provide actionable recommendations for operators in defense, intelligence, border security, logistics and other complex environments. To do that, it combines traditional analytics, AI/ML models, simulation, and mission-planning tools into a single decision-intelligence laye

2026 The New Era – Watchlist Space-AI-Defense

the new era

2026 opens in a geopolitical environment that looks like a “Cold War 2.0” – but running at a much higher speed and across more domains than anything we have seen before. Classic threat pillars – nuclear deterrence, air and sea control, conventional superiority – are still there, but they have been reshaped by disruptive technologies that make them far more lethal and unpredictable.

BFRI Biofrontera Inc

bfri

Photodynamic-therapy specialist with a single commercial franchise (Ameluz + RhodoLED) in U.S. dermatology, entering a dense 2026 data and regulatory window while revenues scale from the low–mid $40M range and the balance sheet remains tight.

PHAR Pharming Group Adr-CRL

pharbis

On February 1, 2026, Pharming announced that the U.S. FDA issued a Complete Response Letter (CRL) to its supplemental New Drug Application (sNDA) for Joenja (leniolisib) in children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS). The letter does not question the fundamental clinical benefit of leniolisib in APDS but raises two specific technical concerns

CRMD CorMedix Inc

crmda

CorMedix is no longer the pre-revenue story that dialysis investors watched from a distance. After the U.S. launch of DefenCath in 2024, the company has delivered its first profitable quarter, acquired the Melinta anti-infective portfolio, built a meaningful cash position and, as of February 2026, added a $75 million share repurchase program on top.

ARTV Artiva Biotherapeutics Inc

artv

Artiva Biotherapeutics is a clinical-stage biotech company focused on off-the-shelf allogeneic NK cell therapies built on a standardized, donor-derived, manufacturing platform. The lead asset, AlloNK (AB-101), is being developed in combination with anti-CD20 therapy both in B-cell non-Hodgkin lymphoma (NHL) and in autoimmune d

SIDU Sidus Space Inc

sidus

From “space-as-a-service” niche player to SHIELD radar contributor: what changed for Sidus Space after our first deep dive, how the December 2025 capital raise reshaped the runway, and why LizzieSat-4 plus AI/ML payloads make 2026 a crucial execution year.

ICU SeaStar Medical Holding Corp

icu

SeaStar Medical is not a typical “pre-clinical biotech on a slide deck”. The company has already crossed the line into real-world use: QUELIMMUNE (the pediatric implementation of the SCD) is approved by the US Food and Drug Administration via HDE and has been adopted by a growing group of leading US children’s hospitals. Early registry data suggest improved survival and kidney recovery in some of the sickest patients in the ICU, with no device-related safety signals reported so far

DRTS Alpha Tau Medical Ltd Jan Update

drts aupdate jan

We wrote our original bullish editorial at the very end of December 2025, when the stock was still trading around five dollars and largely under the radar. January brought ASCO GI pancreatic data, a first PMA module to the FDA, a shareholder letter and a sharp re-rating. Here we revisit the thesis, check the fundamentals and map the next catalysts. Educational only, not investment advice.

CTM Castellum Inc

ctm4

Castellum starts 2026 with exactly what you want to see in a micro-cap defense name: more work, bigger visibility inside the U.S. missile-defense and Navy ecosystem, and a tape that already gave traders a clean spike-and-fade on the first new contract of the year.

POET Technologies Inc Jan Recap

poet1

January 2026 has been anything but quiet for POET Technologies. The stock first extended the late-2025 rerating on the “AI optics” narrative and then got hit hard by a US$150 million registered direct offering that erased most of the month’s gains. The industrial thesis around the Optical Interposer has not changed, but the share count has – and the market is repricing that.

ALLO Allogene Therapeutics Inc

allo

Allogene Therapeutics is not the 2+ billion dollar hype story it was a few years ago. After the initial enthusiasm around off-the-shelf CAR T, the stock has been crushed by a sequence of events: an FDA clinical hold in 2021, years of execution risk, pipeline reshuffling and workforce reductions.

BNAI Brand Engagement Network Inc

bnai

In mid-January we covered BNAI as a tiny, risky AI play with a handful of real enterprise projects and a fragile balance sheet. Two weeks later the stock has printed a 52-week range from $1.18 to an intraday high above $80, short interest has exploded, and the company rushed out multiple press releases on licensing, warrant exercises, debt conversion and a premium private placement. This note is meant to put everything back into one framework: what BEN actually does, what changed in January, how stretched the valuation looks, and which hard catalysts matter once the trading dust settles.

AMRN Amarin Corp ADR Update Jan 31

amrn2

A few years ago, the Amarin story was dominated by a single word: generics. After losing key patent battles on Vascepa, the U.S. business was hit by an aggressive wave of skinny-label competitors, PBM exclusions and net price pressure, to the point where many investors simply filed AMRN under “broken story”. At the start of 2026, the picture is no longer that binary. The company is still far from the glory days, but the trajectory is clearly different: less bleeding, more structure, and a gradual shift from survival mode to controlled recovery.

IBRX ImmunityBio Inc Update Jan 31

IBRXrecap

Since the last Merlintrader pieces on ImmunityBio, the story has accelerated on several fronts. Anktiva net product revenue exploded to a preliminary 113 million dollars for 2025, a roughly 700 percent year-over-year jump with 38.3 million in the fourth quarter alone, backed by strong unit growth and broader coverage in the United States and abroad, as detailed in the company’s mid-January 2026 update and echoed across financial coverage.

Week ahead and recap jan 31 2026

weeka

Week Ahead and Recap – January 31, 2026
Gold near record highs, AI shockwaves in gaming, and a cluster of high-grade biotech catalysts from DF-003 in ROSAH syndrome to camizestrant in ESR1-mutant breast cancer. This is your condensed map for the week.